Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Summary

This is a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age. Subjects will be screened within 28 days of randomization (Day 1).

Timeline

Start

2017-09-18

Primary completion

2018-03-07

Completion

2018-06-15

Drugs

Indications